ALK2 inhibitors and methods for inhibiting BMP signaling

US11026947B2 · kind B2 · utility

Assignees

• The Brigham and Women's Hospital, Inc. · US
• The United States of America as Represented by the Secretary, Dept. of Health and Human Services · US

Inventors

• Paul B. Yu · Boston, US
• Wenwei Huang · Rockville, US
• Philip E. Sanderson · Bethesda, US
• Jian-Kang Jiang · Columbia, US
• Khalida Shamim · Gaithersburg, US
• Wei Zheng · Rockville, US
• Xiuli Huang · Potomac, US
• Gregory J. Tawa · Doylestown, US
• Arthur Lee · San Jose, US
• Asaf Alimardanov · Nanuet, US
• Junfeng Huang · Saint Augustine, US

Key dates

• Filing date: Apr 26, 2018
• Grant date: Jun 8, 2021
• Expiry date: Apr 26, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/6561
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).